Guinness Ventures is pleased to have participated as an investor in Evaro's $25m Series A funding round.
We are delighted to have participated in GlycanAge’s $8.7m (€7.4m) investment targeted funding round. GlycanAge is a biotechnology company transforming how individuals and healthcare providers understand healthy ageing through advanced glycan analysis.
We are delighted to announce our investment in YASO, the operating system for global brands in China, following the close of its £8.26 million Series A funding round.
Guinness Ventures
18 Smith Square
London
SW1P 3HZ
United Kingdom
Phone number:
+44 20 7222 3475
Email:
[email protected]
The value of an investment may fall as well as rise and you may not get back the full amount of your investment. The investment documentation contains more complete and detailed information of risk, charges and expenses that are to be borne by an investor for each product or service. The documentation should be read carefully before investing. Reference to specific securities is not intended as a recommendation to purchase or sell any investment. Please remember that past performance is not a guide to future performance. Retail investors are advised to consult their independent investment adviser before investing. Any data on this website is correct as at 30 April 2025 unless otherwise stated. Telephone calls will be recorded and monitored.
Guinness Ventures Limited (Company No: 13861716) is an appointed representative of Guinness Asset Management Limited (Company No: 4647882), which is authorised and regulated by the Financial Conduct Authority.
